AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

Turning groundbreaking research from the Institut Pasteur with the support of Argobio’s start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections. The platform ...

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

Shareholders sued Allarity over alleged false statements about the prospects for approval of the firm's investigational kidney cancer therapy.

Harnessing the Power of AI to Accelerate Cancer Drug Development ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Insmed Incorporated (NASDAQ: INSM) announced on February 24, 2025 that the U.S. Food and Drug Administration (FDA) does not ...

Scientists at the (UNIGE) have developed a tool that uses light to precisely control where and when a drug becomes active, ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...